Medendi

Medendi means "healing pathway" in Latin. Medendi is the brainchild of Giorgio Pasetto, an emergency physician, and Maurizio Scaltriti, an expert in molecular-targeted therapies, with the goal of making precision oncology medicine available to all patients. The business model was developed with the support of the third founder, Gianmarco Molinari, a manager and marketing expert.

There is an objective gap between advanced oncology science and the treatment protocols applied to patients. The adoption of extended genomic testing-NGS and advanced diagnostics such as proteomic analysis-is still limited in "real-world" healthcare systems, making it difficult to identify all tumor alterations that can be addressed with targeted therapies.

Medendi's goal is to provide easy and timely access to advanced precision oncology for patients and oncologists to:

• gain a thorough understanding of the tumor
• identify and recommend the most appropriate therapeutic strategies
• make a wide range of oncology services available to patients and oncologists
• help prevent cancers
• facilitate the adoption of precision oncology medicine

Medendi is an online platform of services for oncology that makes advanced diagnostics available to patients and oncologists withtherapeutic guidance from international oncologists and researchers. Services are managed remotely and each patient is accompanied by specialists and oncologists along the personalized pathway. It boasts a strong network of partnerships with research centers, clinical institutes and with solid and advanced entities in the field of oncology diagnostics and artificial intelligence applied to oncology. You can get an online consultation with one of the oncologists on Medendi's Scientific Committee.

Medendi's therapeutic targeting is supported by an artificial intelligence engine dedicated to oncology that identifies the most appropriate therapeutic pathways in line with the results of diagnostics and the molecular profile of the tumor, including clinical trials in which the patient can potentially be recruited.

Medendi provides germline mutation testing to patients' family members to detect predisposing inherited alterations. Recently, it introduced access to minimal residual disease (MRD) testing for ultra-early detection of disease recurrence in patients in remission.

In the past 18 months, Medendi has received more than 4,000 clinical records and managed more than 200 patients.

Ancillary services unrelated to the diagnostic and treatment pathway are being introduced; such as support from a psychologist with experience in managing trauma in patients and family members, and nursing services. These services are operated by business partners and offered to patients who contact Medendi.

This campaign provides mandatory or optional Trust Header Service depending on the type of shares subscribed: shares B (Standard or Early Bird) - Mandatory Trust Header; shares A - Free choice between Trust Header or Ordinary Regime.

Tax benefits of 30% apply on Medendi.

Medendi reserves the right of "liquidation preference" for all investors who join the campaign, who will therefore be reimbursed first in the event of an exit than the company's other shareholders (according to the order of preference stated in the bylaws). All conditions are published in the bylaws found in the Documents section.

This is a marketing communication. Equity crowdfunding investments are high-risk and could result in total or partial loss of invested capital. Please read the sheet containing key investment information before joining.